These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38214218)

  • 1. A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics.
    Elkhashab M; Dilek Y; Foss M; Creemers LB; Howard KA
    Mol Pharm; 2024 Feb; 21(2):491-500. PubMed ID: 38214218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin Biomolecular Drug Designs Stabilized through Improved Thiol Conjugation and a Modular Locked Nucleic Acid Functionalized Assembly.
    Dinesen A; Winther A; Wall A; Märcher A; Palmfeldt J; Chudasama V; Wengel J; Gothelf KV; Baker JR; Howard KA
    Bioconjug Chem; 2022 Feb; 33(2):333-342. PubMed ID: 35129956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Albumin-Holliday Junction Biomolecular Modular Design for Programmable Multifunctionality and Prolonged Circulation.
    Dinesen A; Andersen VL; Elkhashab M; Pilati D; Bech P; Fuchs E; Samuelsen TR; Winther A; Cai Y; Märcher A; Wall A; Omer M; Nielsen JS; Chudasama V; Baker JR; Gothelf KV; Wengel J; Kjems J; Howard KA
    Bioconjug Chem; 2024 Feb; 35(2):214-222. PubMed ID: 38231391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin-Binding Fatty Acid-Modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics.
    Cai Y; Lou C; Wengel J; Howard KA
    Methods Mol Biol; 2020; 2176():163-174. PubMed ID: 32865790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis.
    Garcia JP; Stein J; Cai Y; Riemers F; Wexselblatt E; Wengel J; Tryfonidou M; Yayon A; Howard KA; Creemers LB
    J Control Release; 2019 Jan; 294():247-258. PubMed ID: 30572032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity.
    Cai Y; Makarova AM; Wengel J; Howard KA
    J Gene Med; 2018 Jul; 20(7-8):e3025. PubMed ID: 29800498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hyaluronic acid-based hydrogel enabling CD44-mediated chondrocyte binding and gapmer oligonucleotide release for modulation of gene expression in osteoarthritis.
    Cai Y; López-Ruiz E; Wengel J; Creemers LB; Howard KA
    J Control Release; 2017 May; 253():153-159. PubMed ID: 28274742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
    Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
    Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding.
    Kusznir EA; Hau JC; Portmann M; Reinhart AG; Falivene F; Bastien J; Worm J; Ross A; Lauer M; Ringler P; Sladojevich F; Huber S; Bleicher K; Keller M
    Bioconjug Chem; 2023 May; 34(5):866-879. PubMed ID: 37145959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1α.
    Li H; Quan J; Zhang M; Yung BC; Cheng X; Liu Y; Lee YB; Ahn CH; Kim DJ; Lee RJ
    Mol Pharm; 2016 Jul; 13(7):2555-62. PubMed ID: 27253378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
    Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
    J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-RNA Heteroduplex Oligonucleotide for Highly Efficient Gene Silencing.
    Hara RI; Yoshioka K; Yokota T
    Methods Mol Biol; 2020; 2176():113-119. PubMed ID: 32865786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates.
    Boado RJ; Pardridge WM
    Bioconjug Chem; 1994; 5(5):406-10. PubMed ID: 7849069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.
    Schmidt EGW; Hvam ML; Antunes F; Cameron J; Viuff D; Andersen B; Kristensen NN; Howard KA
    J Biol Chem; 2017 Aug; 292(32):13312-13322. PubMed ID: 28637874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of gapmer antisense oligonucleotide with deoxyribonucleic guanidine (DNG) modifications.
    Kojima N; Shrestha AR; Akisawa T; Piao H; Kizawa H; Ohmiya Y; Kurita R
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):258-269. PubMed ID: 31556356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications.
    Kuhlmann M; Hamming JBR; Voldum A; Tsakiridou G; Larsen MT; Schmøkel JS; Sohn E; Bienk K; Schaffert D; Sørensen ES; Wengel J; Dupont DM; Howard KA
    Mol Ther Nucleic Acids; 2017 Dec; 9():284-293. PubMed ID: 29246307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.